MedTrace Logo

Ramelteon in Adults With Chronic Insomnia

NCT00671567 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 848

Last updated 2012-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of Ramelteon, once daily (QD), in adult subjects with chronic insomnia.

Conditions

  • Chronic Insomnia

Interventions

DRUG

Ramelteon

Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.

DRUG

Ramelteon

Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.

DRUG

Placebo

Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.

Sponsors & Collaborators

Principal Investigators

  • VP, Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2003-09-30
Completion
2003-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00671567 on ClinicalTrials.gov